TY - JOUR
T1 - Corrigendum to “Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics” “Antiviral Research 209 (2023)/105484” (Antiviral Research (2023) 209, (S0166354222002534), (10.1016/j.antiviral.2022.105484))
AU - Perez-Vargas, Jimena
AU - Shapira, Tirosh
AU - Olmstead, Andrea D.
AU - Villanueva, Ivan
AU - Thompson, Connor A.H.
AU - Ennis, Siobhan
AU - Gao, Guang
AU - De Guzman, Joshua
AU - Williams, David E.
AU - Wang, Meng
AU - Chin, Aaleigha
AU - Bautista-Sanchez, Diana
AU - Agafitei, Olga
AU - Levett, Paul
AU - Xie, Xuping
AU - Nuzzo, Genoveffa
AU - Freire, Vitor F.
AU - Quintana-Bulla, Jairo I.
AU - Bernardi, Darlon I.
AU - Gubiani, Juliana R.
AU - Suthiphasilp, Virayu
AU - Raksat, Achara
AU - Meesakul, Pornphimol
AU - Polbuppha, Isaraporn
AU - Cheenpracha, Sarot
AU - Jaidee, Wuttichai
AU - Kanokmedhakul, Kwanjai
AU - Yenjai, Chavi
AU - Chaiyosang, Boonyanoot
AU - Teles, Helder Lopes
AU - Manzo, Emiliano
AU - Fontana, Angelo
AU - Leduc, Richard
AU - Boudreault, Pierre Luc
AU - Berlinck, Roberto G.S.
AU - Laphookhieo, Surat
AU - Kanokmedhakul, Somdej
AU - Tietjen, Ian
AU - Cherkasov, Artem
AU - Krajden, Mel
AU - Nabi, Ivan Robert
AU - Niikura, Masahiro
AU - Shi, Pei-Yong
AU - Andersen, Raymond J.
AU - Jean, François
N1 - Publisher Copyright:
© 2023 The Author(s)
PY - 2023/5
Y1 - 2023/5
N2 - The authors regret the need to clarify the sources of support listed in the acknowledgements. Original text: “PYS was supported by NIH grants HHSN272201600013C, U01AI151801, and U19AI171413, and awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation, and the Summerfield Robert Foundation.” Revised text: “PYS was supported by awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation, and the Summerfield Robert Foundation.”>. The authors would like to apologise for any inconvenience caused.
AB - The authors regret the need to clarify the sources of support listed in the acknowledgements. Original text: “PYS was supported by NIH grants HHSN272201600013C, U01AI151801, and U19AI171413, and awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation, and the Summerfield Robert Foundation.” Revised text: “PYS was supported by awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation, and the Summerfield Robert Foundation.”>. The authors would like to apologise for any inconvenience caused.
UR - http://www.scopus.com/inward/record.url?scp=85151261481&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151261481&partnerID=8YFLogxK
U2 - 10.1016/j.antiviral.2023.105577
DO - 10.1016/j.antiviral.2023.105577
M3 - Comment/debate
C2 - 37002158
AN - SCOPUS:85151261481
SN - 0166-3542
VL - 213
JO - Antiviral research
JF - Antiviral research
M1 - 105577
ER -